VA111913

VA111913 is an orally active small molecule drug developed for the prevention and treatment of dysmenorrhoea (painful menstrual cramps). It acts as a selective antagonist of the vasopressin 1a receptor (V1a receptor) in smooth muscle tissue of the uterus. By blocking this receptor, VA111913 reduces abnormal uterine contractions and improves blood flow to the uterus—mechanisms believed to underlie pain in dysmenorrhoea. The drug was discovered by Vantia Therapeutics through compound screening and subsequent optimization for oral administration and potency. Clinical development reached Phase II trials but there have been no recent reports of further progress[2][3][5][7].

Other names

VA-111913 TSVA111913 TSVA 111913 TSVA-913VA913VA 913VT-913VT913VT 913VantiaVasopressin 1a antagonists (dysmenorrhea)Vantia/Ferring